Rethinking Diabetes: A Weekly Review
Malattie Metaboliche e Diabetologia
Insulin Therapy Complications and Diabetes Management Updates
This week's episode explores complications of insulin therapy including lipohypertrophy and gastroparesis, examines diabetes screening approaches, and discusses lipid management in high-risk patients. We review nine key studies with clinical implications for diabetes care.
Bibliography
1. Risk factors for Lipohypertrophy in People With Insulin-Treated Diabetes: A Systematic Meta-Analysis.
Authors: Mader JK, Fornengo R, Hassoun A, et al.
Journal: Journal of diabetes science and technology, 2026 Jul
PMID: 40109173
DOI: 10.1177/19322968251325569
2. The Relationship Between the Percent Coefficient of Variation of Sensor Glucose Levels and the Risk of Severe Hypoglycemia or Non-Severe Hypoglycemia in Patients With Type 1 Diabetes: Post Hoc Analysis of the ISCHIA Study.
Authors: Murata T, Matsuhisa M, Kuroda A, et al.
Journal: Journal of diabetes science and technology, 2026 Jul
PMID: 39960254
DOI: 10.1177/19322968251318756
3. Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics.
Authors: Bork C, Nordestgaard BG, Hedegaard BS, et al.
Journal: Atherosclerosis, 2026 Jul
PMID: 42178198
DOI: 10.1016/j.atherosclerosis.2026.120757
4. Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study.
Authors: Toplak H, Komen JJ, Bardet A, et al.
Journal: BMJ open, 2026 Jun 29
PMID: 42373176
DOI: 10.1136/bmjopen-2025-108737
5. Autoimmune encephalitis-associated epilepsy with glutamic acid decarboxylase autoantibodies and type 1 diabetes mellitus: A comprehensive systematic scoping review of a clinical syndrome.
Authors: Kouhanjani MF, Plautz A, Melzer N, et al.
Journal: Autoimmunity reviews, 2026 Jul
PMID: 42173229
DOI: 10.1016/j.autrev.2026.104091
6. Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression.
Authors: Marassi M, Pollis RM, Fadini GP
Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD, 2026 Jul
PMID: 41997798
DOI: 10.1016/j.numecd.2026.104714
7. A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening.
Authors: Hillier TA, Pedula KL, Ogasawara KK, et al.
Journal: The New England journal of medicine, 2021 Mar 11
PMID: 33704936
DOI: 10.1056/NEJMoa2026028
8. Diabetic gastroparesis: pathophysiology and impact on insulin timing choices.
Authors: Galeano F, Tumminia A, Oteri V, et al.
Journal: Endocrine, 2026 Jun 23
PMID: 42334698
DOI: 10.1007/s12020-026-04693-6
9. Existing Knowledge Gaps in Risk Factors and Consequences of Lipohypertrophy in People Using Continuous Subcutaneous Insulin Infusion Therapy: A Systematic Review and Meta-analysis.
Authors: Mader JK, Fornengo R, Hassoun A, et al.
Journal: Journal of diabetes science and technology, 2026 Jul
PMID: 40119628
DOI: 10.1177/19322968251319806
Authors: Mader JK, Fornengo R, Hassoun A, et al.
Journal: Journal of diabetes science and technology, 2026 Jul
PMID: 40109173
DOI: 10.1177/19322968251325569
2. The Relationship Between the Percent Coefficient of Variation of Sensor Glucose Levels and the Risk of Severe Hypoglycemia or Non-Severe Hypoglycemia in Patients With Type 1 Diabetes: Post Hoc Analysis of the ISCHIA Study.
Authors: Murata T, Matsuhisa M, Kuroda A, et al.
Journal: Journal of diabetes science and technology, 2026 Jul
PMID: 39960254
DOI: 10.1177/19322968251318756
3. Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics.
Authors: Bork C, Nordestgaard BG, Hedegaard BS, et al.
Journal: Atherosclerosis, 2026 Jul
PMID: 42178198
DOI: 10.1016/j.atherosclerosis.2026.120757
4. Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study.
Authors: Toplak H, Komen JJ, Bardet A, et al.
Journal: BMJ open, 2026 Jun 29
PMID: 42373176
DOI: 10.1136/bmjopen-2025-108737
5. Autoimmune encephalitis-associated epilepsy with glutamic acid decarboxylase autoantibodies and type 1 diabetes mellitus: A comprehensive systematic scoping review of a clinical syndrome.
Authors: Kouhanjani MF, Plautz A, Melzer N, et al.
Journal: Autoimmunity reviews, 2026 Jul
PMID: 42173229
DOI: 10.1016/j.autrev.2026.104091
6. Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression.
Authors: Marassi M, Pollis RM, Fadini GP
Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD, 2026 Jul
PMID: 41997798
DOI: 10.1016/j.numecd.2026.104714
7. A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening.
Authors: Hillier TA, Pedula KL, Ogasawara KK, et al.
Journal: The New England journal of medicine, 2021 Mar 11
PMID: 33704936
DOI: 10.1056/NEJMoa2026028
8. Diabetic gastroparesis: pathophysiology and impact on insulin timing choices.
Authors: Galeano F, Tumminia A, Oteri V, et al.
Journal: Endocrine, 2026 Jun 23
PMID: 42334698
DOI: 10.1007/s12020-026-04693-6
9. Existing Knowledge Gaps in Risk Factors and Consequences of Lipohypertrophy in People Using Continuous Subcutaneous Insulin Infusion Therapy: A Systematic Review and Meta-analysis.
Authors: Mader JK, Fornengo R, Hassoun A, et al.
Journal: Journal of diabetes science and technology, 2026 Jul
PMID: 40119628
DOI: 10.1177/19322968251319806
